Cleo Diagnostics Limited completes its listing of shares on the ASX
Cleo Diagnostics Limited (ASX:COV) is a medical diagnostics/devices entity focused on the development of non-invasive blood based IVD tests to detect the presence, and recurrence of ovarian cancer. The underlying technology was initially discovered and developed at the Hudson Institute of Medical Research, in Melbourne, Australia.
The company is focussed on the development and commercialisation of the three related tests for ovarian cancer detection:
- Triage test – A pre-surgical test to determine the likelihood that a pre-surgical ovarian mass in a patient not yet referred to an oncologist is malignant
- Recurrence test – A post-surgical test to identify whether a cancer is recurring following surgical removal and chemotherapy of cancerous tissue
- Screening test – A screening test to identify early-stage ovarian cancer in patients who do not present any symptoms consistent with ovarian cancer.
Cleo was established to leverage Hudson’s research to provide a public platform to raise capital and accelerate the development and commercialisation of the Tests.
The company has completed its listing of shares on the Australian Securities Exchange (ASX), raising a total of A$12 million in capital.
BDO was engaged by Cleo to provide audit and investigating accountant services for the IPO.